EXPERIMENTAL AND CLINICAL PHARMACOLOGY OF RIFAXIMIN SELECTIVE ENTERIC ANTIBIOTIC

EXPERIMENTAL AND CLINICAL PHARMACOLOGY OF RIFAXIMIN SELECTIVE ENTERIC ANTIBIOTIC

Show other versions (1)

Solvay pharma expands its product portfolio, by launching alfa normix (rifaximin) for the treatment of the gastroenteric infections. Alfa normix is a non-systemic broad-spectrum antibiotic to treat acute gastroenteric infections and is prescribed for the travelers suffering from diarrhea, the overgr...

Full description

Bibliographic Details
Main Author:	article editorial
Format:	Article
Language:	English
Published:	Paediatrician Publishers, LLC 2008-05-01
Series:	Pediatričeskaâ Farmakologiâ
Online Access:	https://www.pedpharma.ru/jour/article/view/868

Similar Items

EXPERIMENTAL AND CLINICAL PHARMACOLOGY OF RIFAXIMIN SELECTIVE ENTERIC ANTIBIOTIC
by: article editorial
Published: (2008-05-01)

RIFAXIMIN TO TREAT OF GASTROINTESTINAL INFECTIONS
by: article editorial
Published: (2008-06-01)

RIFAXIMIN TO TREAT OF GASTROINTESTINAL INFECTIONS
by: article editorial
Published: (2008-01-01)

Rifaximin: unique selective antibiotic for the treatment of gastrointestinal diseases
by: E. Yu. Plotnikova
Published: (2021-05-01)

Clinical experience with the use of the intestinal antibiotic Rifaximin for celiac disease
by: L. S. Оrеshkо, et al.
Published: (2019-10-01)

Rifaximin for maintenance therapy in antibiotic-dependent pouchitis
by: Lopez A Rocio, et al.
Published: (2008-06-01)

Liver Fibrosis and Rifaximin
by: Ki Tae Suk
Published: (2017-11-01)

Effects of the antibiotic rifaximin on cortical functional connectivity are mediated through insular cortex
by: Davide Sometti, et al.
Published: (2021-02-01)

Clinical Response of Rifaximin Treatment in Patients with Abdominal Bloating
by: Kichul Yoon, et al.
Published: (2018-09-01)

Efficacy of rifaximin in the different clinical scenarios of hepatic encephalopathy
by: C.E. Coronel-Castillo, et al.
Published: (2020-01-01)

Rifaximin in the treatment of hepatic encephalopathy
by: Iadevaia MD, et al.
Published: (2011-12-01)

Mitochondrial Side Effects of Surgical Prophylactic Antibiotics Ceftriaxone and Rifaximin Lead to Bowel Mucosal Damage
by: Baráth, B., et al.
Published: (2022)

Rifaximin Therapy of Irritable Bowel Syndrome
by: Hoonmo L. Koo, et al.
Published: (2012-01-01)

Rifaximin for Pertuzumab-Related GI Toxicities
by: Aixa E. Soyano, et al.
Published: (2017-08-01)

Rifaximin Therapy of Irritable Bowel Syndrome
by: Hoonmo L. Koo, et al.
Published: (2012-06-01)

Impact of crystal polymorphism on the systemic bioavailability of rifaximin, an antibiotic acting locally in the gastrointestinal tract, in healthy volunteers
by: Blandizzi C, et al.
Published: (2014-12-01)

Erratum: Shifrin O.S. et al., “Russian Non Interventional Study of the Efficacy and Tolerability of Rifaximin Therapy in Patients with Uncomplicated Diverticular Disease under the Conditions of Outpatient Practice”
by: article Editorial
Published: (2020-07-01)

Rifaximin as treatment for hepatic encephalopathy: Some considerations
by: Lorenzo Ridola, et al.
Published: (2013-01-01)

Rifaximin has the potential to prevent complications of cirrhosis
by: Steven L. Flamm, et al.
Published: (2018-09-01)

Use of Rifaximin in Irritable Bowel Syndrome Treatment
by: Hubert Wróblewski, et al.
Published: (2021-08-01)

The role of Rifaximine-α in traveler’s diarrhea therapy
by: Victoria Aramă, et al.
Published: (2016-03-01)

Combination of rifaximin and lactulose improves clinical efficacy and mortality in patients with hepatic encephalopathy
by: Wang Z, et al.
Published: (2018-12-01)

Selective improvement by rifaximin of changes in the immunophenotype in patients who improve minimal hepatic encephalopathy
by: Alba Mangas-Losada, et al.
Published: (2019-08-01)

Monaldi Archives for Chest Disease enters Clinical Pharmacology officially
by: R.W. Dal Negro, et al.
Published: (2016-01-01)

COMPLEX TREATMENT OF HELICOBACTER PYLORI INFECTION WITH RIFAXIMIN IN CHILDREN
by: A.A. Nizhevich, et al.
Published: (2009-11-01)

Efficacy of and Resistance to Rifaximin-based Quadruple Therapy in Eradication
by: Hyun Soo Kim, et al.
Published: (2020-09-01)

Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy
by: Kimer N, et al.
Published: (2014-03-01)

COMPLEX TREATMENT OF HELICOBACTER PYLORI INFECTION WITH RIFAXIMIN IN CHILDREN
by: A.A. Nizhevich, et al.
Published: (2009-01-01)

Review of Rifaximin: Latest Treatment Frontier for Irritable Bowel Syndrome Mechanism of Action and Clinical Profile
by: Kamesh Gupta, et al.
Published: (2017-08-01)

Biological and Pharmacological Factor that Influence the Selection of Antibiotic Resistance
by: Gustafsson, Ingegerd
Published: (2003)

Rifaximin ameliorates intestinal inflammation in cirrhotic patients with hepatic encephalopathy
by: Yasuyuki Tamai, et al.
Published: (2021-07-01)

Uncommon Movement Disorders in Chronic Hepatic Disease with Response to Rifaximin
by: Ana L. Sousa, et al.
Published: (2019-08-01)

EVALUATION OF EFFICACY OF RIFAXIMIN IN THE TREATMENT OF HEPATIC ENCEPHALOPATHY IN PATIENTS WITH CIRRHOSIS
by: Hafsa Habib, et al.
Published: (2016-12-01)

The role of rifaximin in the treatment and chemoprophylaxis of travelers&#39; diarrhea
by: Hoonmo L Koo, et al.
Published: (2009-10-01)

Profile of rifaximin and its potential in the treatment of irritable bowel syndrome
by: Iorio N, et al.
Published: (2015-06-01)

Quantification of Rifaximin in Tablets by Spectrophotometric Method Ecofriendly in Ultraviolet Region
by: Ana Carolina Kogawa, et al.
Published: (2016-01-01)

Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy.
by: Jasmohan S Bajaj, et al.
Published: (2013-01-01)

ECO-FRIENDLY AND MINIATURIZED ANALYTICAL METHOD FOR QUANTIFICATION OF RIFAXIMIN IN TABLETS
by: Clara Bersi Motta Correa, et al.
Published: (2019-12-01)

Role of non-absorbable oral antibiotics in bowel preparation for intracavitary brachytherapy: effects of rifaximin on rectal dosimetric parameters during vaginal cuff brachytherapy
by: Sasan Razmjoo, et al.
Published: (2021-08-01)

Effects of Rifaximin on Luminal and Wall-Adhered Gut Commensal Microbiota in Mice
by: Marina Ferrer, et al.
Published: (2021-01-01)